Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to site content Skip directly to page options
CDC Home

About TATFAR

The growing global threat of AMR was recognized by US President Obama, Swedish Prime Minister and then-European Council President Reinfeldt, and European Commission President Barroso at the 2009 US – EU summit. The summit declaration called for the establishment of “― a transatlantic taskforce on urgent AMR issues focused on three key areas: 1- appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, 2- prevention of both healthcare- and community-associated drug-resistant infections, and 3- strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.”. The Transatlantic Taskforce on Antimicrobial Resistance (TATFAR) was constituted based on this declaration.

TATFAR identified and adopted 17 recommendations for future collaborations between the US and the EU. Collaboration between the US and the EU has led to increased information exchange, understanding of best approaches and practices, and development of peer relationships. While significant progress has been made, concern related to antimicrobial resistance (AMR) continues to escalate. Therefore, the mandate of the taskforce has been extended for two additional years. In May 2014, the taskforce will released a report summarizing the progress and the outcomes of the implementation of the 17 recommendations.  The taskforce decided to continue with 15 recommendations, retiring two recommendations, and created one new recommendation for collaboration over the next two-year period.

CDC currently provides the secretariat for the task force and publishes documents relating to the work of the task force on this website. The European Centre for Disease Prevention and Control (ECDC) provided the secretariat from 2009-2013.

Member Organizations

U.S. Organizations


EU Organizations

Top of Page

Terms of Reference

Key Focus Areas


The work of the taskforce is guided by the Key Areas defined by the 2009 EU–US Summit declaration "to establish a transatlantic taskforce on urgent AMR issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us".

The three Key Areas are:

  1. Appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities
  2. Prevention of drug-resistant infections
  3. Strategies to improve the pipeline of new antibacterial drugs for use in human medicine

Composition and structure of the taskforce

Members:

The taskforce and any related working groups shall be composed of members of the civil service and/or other government officials of the EU and the US. The members shall have a general overview on health-related issues or a specific knowledge on AMR in one of the three Key Focus Areas. At the start of this TATFAR period (2014 – 2016) the taskforce will consist of 18 members (up to nine from the US and up to nine from the EU) and the secretariat.

The United States will be represented by the following agencies or offices of the Department of Health and Human Services:

  • Office of Global Affairs (OGA)
  • Centers for Disease Control and Prevention (CDC)
  • Food and Drug Administration (FDA)
  • National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIH/NIAID)

The European Union will be represented by the following agencies and organisations:

European Commission:

  • EC Directorate-General for Health and Consumers (two representatives)
  • EC Directorate-General for Research
  • European Centre for Disease Prevention and Control (ECDC)
  • European Medicines Agency (EMA)
  • European Food Safety Authority (EFSA)

Council of the European Union, represented by the Trio Presidency in order to keep the Council regularly informed of progress.

Members will:

  • Participate in biannual TATFAR meetings
  • Identify implementers for recommendations for collaboration
  • Review and approve TATFAR outputs including, but not limited to, changes to recommendations for collaboration, progress reports and meeting minutes

Implementers:

The TATFAR members will identify technical experts (implementers) to work on recommendations for collaboration. 

Implementers will:

  • Collaborate on the accomplishment of recommendations
  • Report on the progress for each recommendation no less than quarterly

Key Area Working Groups:

Each of the three Key Areas of the taskforce will have a working group headed by a Lead and Co-Lead to monitor the progress of existing recommendations and to develop new recommendations.  The Lead and Co-Lead will be TATFAR members and will be nominated by the taskforce.  The working groups will consist of implementers under the respective Key Area.

Top of Page

Key area working groups

Operation Procedures


The taskforce is co-chaired by the Director of the European Commission Public Heath Directorate and US Assistant Secretary for Global Affairs.  The full membership of the taskforce will hold meetings no less than every six months by teleconference with one in-person meeting every two years.  The taskforce will issue a report on its progress every two years.

There will be a working group for each of the three Key Areas of focus.  Each working group will be comprised of a lead and co-lead from the TATFAR membership and implementers for the recommendations under each Key Area.   The working groups will hold quarterly meetings by teleconference to monitor progress on the implementation of existing recommendations, develop new recommendations, or propose the retirement of recommendations.

Recommendations for Collaboration


Ongoing Recommendations:

Implementers for each recommendation will establish their own schedules for meetings and correspondence.  Implementers will report on the progress for each recommendation to the Key Area Working group Co-Leads no less than quarterly. 

Retiring Recommendations:

A Key Area Working group may propose to retire a recommendation if progress is stalled or work has been completed.  The Co-leads for each working group will present a proposal for the retirement of a recommendation, including justification, to the full TATFAR.  This may be done via email or at a full TATFAR meeting.

New Recommendations:

A Key Area Working group may propose new recommendations for collaboration to the TATFAR.  The Co-leads will be responsible for drafting the recommendation and presenting it to the full TATFAR via email or at a meeting. 

The proposal for a new recommendation shall include:

  • The Key Focus Area under which the recommendation will be included
  • The area of collaboration
  • A brief statement describing the issue
  • Description of the recommendation
  • Proposed implementers
  • Proposed timeline for the implementation of the recommendation

The TATFAR will review proposals for new recommendations for collaboration.  In some cases the TATFAR may require a feasibility assessment before the proposed recommendation can be approved.

Consultation, external interaction and workshops

The members of the taskforce will seek where appropriate, to obtain input from the public, interested experts and other stakeholders, in accordance with each member‘s respective process for obtaining public comment, on the specific activities within the framework of the Declaration where member collaboration can be most fruitful.  As feasible, meetings to which public participation is invited will be conducted not less than every two years. 

Top of Page

 
Contact Us:
  • Centers for Disease Control and Prevention
    1600 Clifton Rd
    Atlanta, GA 30333
  • 800-CDC-INFO
    (800-232-4636)
    TTY: (888) 232-6348
  • Contact CDC–INFO
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #